Resources We partner with pharma to advance neuroscience research All ResourcesWebinarsConferencesPress ReleasesIn the newsPublications SOT 64th Annual Meeting and ToxExpo February 14, 2025 | Conferences Read More → WORD+ 2025 World Organoid and Organ-on-a-Chip Research Day January 24, 2025 | Conferences Read More → Predicting Clinical Neurotoxicity Using Functional Organoids January 14, 2025 | Webinars Read More → Clinically Related Rare Neurodevelopmental Disorders Display Distinct Functional Phenotypes in Human Featured at SfN 2024 October 5, 2024 | Conferences Read More → Modulation of Glial Differentiation in a 3D iPSC-derived CNS Model Featured at SfN 2024 October 5, 2024 | Conferences Read More → Onset of CIPN Delayed Through SARM1 Inhibition in Human NerveSim Preclinical Drug-Discovery Platform Featured at SfN 2024 October 5, 2024 | Conferences Read More → AxoSim Appoints Stuart Gibb as Vice President of Sales and Marketing to Drive Revenue Growth September 17, 2024 | Press Releases Read More → Assessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity September 16, 2024 | Publications Read More → AxoSim Speaks at 2024 ADC Toxicity Summit July 25, 2024 | Conferences Read More → MPS Features Three AxoSim Scientists at 2024 World Summit June 25, 2024 | Conferences Read More → AxoSim Appoints Alif Saleh as Chief Executive Officer to Drive Market Adoption June 11, 2024 | Press Releases Read More → Comparative assessment of Ca2+ oscillations in 2- and 3-dimensional hiPSC derived and isolated cortical neuronal networks May 24, 2024 | Publications Read More → AxoSim Posters Featured at SOT 2024 Annual Meeting  March 26, 2024 | Conferences Read More → AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors February 28, 2024 | Press Releases Read More → Fierce Biotech: Organoids touted as future of brain disorder R&D as AxoSim scoops up tech from Vyant subsidiary December 15, 2023 | In the news Read More → 1 2 3 Next »
